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Abstract 
Introduction 
Epstein Barr Virus (EBV) and Kaposi’s sarcoma associated herpesvirus (KSHV) are 
transmitted via saliva but factors associated with salivary shedding are unknown.  
Methods 
We measured the shedding of both viruses in the saliva of ~500 Ugandan mothers and their 
six-year old children, testing all participants for EBV and KSHV seropositive individuals for 
KSHV.  
Results 
EBV and KSHV were shed by 72% and 22% of the mothers, and by 85% and 40% of 
children, respectively; boys were more likely than girls to shed KSHV (48% versus 30%), but 
not EBV. Children shed more KSHV and EBV than mothers, however salivary of loads EBV 
and KSHV were similar. KSHV shedding increased with increasing anti-KSHV (K8.1) 
antibodies in mothers and with decreasing anti-malarial antibodies both in mothers and 
children. Among mothers, 40% of KSHV shedders also shed EBV, compared to 75% of 
KSHV non-shedders; for children, it was 65% versus 83%.  
Conclusions 
In summary, in this population, individuals were more likely to shed EBV than KSHV in 
saliva; we have identified several factors, including child’s sex, that influence KSHV 
shedding, and an inverse relationship between EBV and KSHV shedding, suggesting a direct 
or indirect interaction between the two viruses.  
KEY WORDS: EBV, KSHV, saliva, shedding, Uganda 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy262/4995546
by London School of Hygiene & Tropical Medicine user
on 17 May 2018
Ac
ce
pte
d M
an
us
cri
pt
 
3 
 
Introduction 
Kaposi’s sarcoma associated herpesvirus (KSHV) is a necessary cause of Kaposi’s sarcoma 
(KS) [1, 2]. Unlike other human herpesviruses, KSHV is not ubiquitous across human 
populations; rather, the prevalence of infection shows considerable geographical variation, 
largely mirroring the variations seen in the incidence of KS. KSHV prevalence is relatively 
high in sub-Saharan Africa, lower in some Mediterranean countries and lowest in most 
northern European and Asian populations [3], suggesting, in part, difference in transmission 
across regions. The factors that sustain higher rates of transmission in sub-Saharan Africa 
compared to most other parts of the world are unclear. In Africa, primary infection begins in 
childhood and prevalence increases with age. KSHV is shed in saliva [1, 4, 5], and this is the 
primary mode of transmission[1].  Conversely, infection by the related gammaherpesvirus, 
Epstein Barr virus (EBV), which is also causes a number of human malignancies, is highly 
prevalent in all human populations[6]. Like KSHV, EBV is transmitted via saliva, but, in low 
income settings, infection generally occurs much earlier in childhood, compared to high 
income settings [7]. 
To investigate possible explanations for the differing epidemiology of these viruses, we 
compare here the prevalence and determinants of shedding of KSHV and EBV in saliva of 
apparently healthy people from a population in Uganda with high KSHV seroprevalence, on 
the assumption that viral shedding is an essential step in transmission [8].  We examined 
sociodemographic, clinical and serological factors, including exposure to helminths and 
malaria, as, in previous work within this cohort, we have found these factors to be associated 
with KSHV seroprevalence[9, 10].   
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Methods 
 
This was a cross sectional study carried out within the context of a clinical trial, the Entebbe 
Mother and Baby study (EMaBS) (ISRCTN32849447). EMaBS is an ongoing birth cohort 
that originated as a double blind randomised placebo-controlled trial designed to determine 
the impact of helminth infections and their treatment on vaccine responses and infectious 
diseases outcomes; the details have been reported elsewhere [11, 12][3, 4]. A total of 2507 
pregnant women from Entebbe, Uganda, who consented, were enrolled into EMaBS and they 
and their children continue to be followed. In 2010, we systematically recruited into this sub-
study consenting HIV negative mothers and their children, seen sequentially in the follow-up 
clinic. Additional plasma samples, together with a saliva sample, were collected and stored 
from both mother and child. Three mothers who had seroconverted for HIV after enrolment 
in the original study were excluded.  
Stored plasma samples from mothers, and from their 6-year old children, were tested for the 
presence of KSHV antibodies using two Enzyme-linked Immunosorbent Assays (ELISA) 
employing KSHV recombinant proteins, a lytic structural glycoprotein, K8.1 and the main 
latent nuclear protein, the latency- associated nuclear antigen (LANA) encoded by ORF73. 
Results are reported as optical densities (ODs). Each plate contained three positive and three 
negative controls; each assay cut-off was calculated based on the performance of the negative 
controls. This procedure has been reported elsewhere [13][5]. Individuals positive in either 
assay were considered KSHV seropositive.  
The same plasma samples were tested for malaria antibodies using two P. falciparum 
antigens: merozoite surface protein (MSP)-1 and apical membrane antigen (AMA)-1 [14][6]. 
A pool of malaria positive plasma samples from patients known to be infected with malaria 
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was used to make standard dilutions. This pool was diluted serially five times starting from 
1:50 for MSP-1 and 1:100 for AMA-1 to make 6 standards with a four-fold dilution 
increment.  Blank wells were used to subtract background absorbance from the standards and 
the samples. ODs obtained were then exported into Microsoft Excel and antibody titres for 
each sample and each antigen were derived from the standard curve of ODs. This procedure 
has been reported elsewhere [15][7]. 
Saliva was collected by having participants rinse their mouth with alcohol-based mouthwash 
and subsequently discharge this fluid into a 50-mL conical tube. DNA was extracted using 
Qiagen blood and body fluids kit according to the manufacturer’s instructions.   
KSHV viral load was measured using a quantitative real-time PCR assay targeting the K6 
gene [16, 17][9, 10]. Similarly, EBV viral load was determined using a quantitative real-time 
PCR specific for the EBNA1 gene [18][11]. Another real-time assay for the human 
endogenous retrovirus 3 (ERV-3), present at two copies in each diploid cell, was used to 
quantify cellular DNA [19][12]. For each real-time PCR assay, each sample was assayed in 
triplicate and an average of the three individual reactions was used to estimate the number of 
copies of the target gene. DNA viral load was then calculated as viral copies (genome 
equivalents) per million cells. Samples were designated qualitative positive if they could not 
be reliably quantitated, i.e. if all three replicates amplified over threshold, but the average 
viral copy number was less than three in the KHSV assay, or less than 10 in the EBV assay, 
or if the sample failed to amplify in one or two of the three triplicate reactions. Qualitative 
positive samples were retested, and if the results were confirmed, they were assigned the 
arbitrary value of one viral copy in further analyses. All mothers and children were tested for 
EBV viral load in saliva, while KSHV seropositive individuals were also tested for KSHV 
viral load.   
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Data analysis preparations involved generating binary outcome variables for KSHV viral load 
shedding, creating binary and categorical variables for demographic, socioeconomic and 
illness information, as well as serological variables including malaria antibody titres and 
KSHV antibody levels. For quantitative analyses, viral loads were log10-transformed.  
Variables considered to be possible risk factors / confounders for shedding in children were 
sex of child, maternal age (categorised as 14-19, 20-24, 25-29, 30-34 and 35+), maternal 
education (none or primary, secondary, tertiary), parity (1, 2-4 or 5+ pregnancies), household 
social economic status, whether mother was shedding or not, helminthiasis, anaemia, anti-
KSHV antibody levels (anti-K8.1 antigen and ORF73 antigen, tertiles), anti-malaria antibody 
levels (tertiles). For shedding in mothers, possible risk factors considered were age, 
education, household socioeconomic status, HIV infection, anaemia, helminthiasis, anti-  
KSHV and anti-malaria antibody levels. Because analysis on KSHV shedding is subset on 
KSHV seropositive individuals, anti-KSHV antibody tertiles include only values predefined 
as positive, whilst anti-malaria antibody levels include the entire range encountered in the 
sample. 
Initial analysis involved generating descriptive statistics by cross-tabulating viral load 
shedding outcome variables and demographic, socioeconomic, illness and immunologic 
variables that were considered to be possible risk factors for shedding. 
Logistic and linear regression models were fitted to examine variables predictive of shedding 
and viral load, respectively; nested modelling was used when twin children were included. 
Both prior knowledge from previous studies and a p<0.05 level of significance in univariate 
analyses were used to select factors to be included in multivariable analyses. Likelihood ratio 
tests were used to determine adjusted p-values. Analyses were conducted using STATA v. 
13.1 (StataCorp, College Station, Texas, USA). 
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Ethics Statement 
This study was approved by the Science and Ethics Committee (SEC) of the Uganda Virus 
Research Institute (UVRI), Uganda National Council for Science and Technology (UNCST) 
and the London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics 
Committee. Written and verbal information was provided in English and the vernacular; 
informed consent was obtained according to the Declaration of Helsinki, and was recorded by 
signature or, in case of participant’s inability to provide a signature, by thumbprint, as 
approved by the study’s IRBs. In Uganda, minors who are married, pregnant or have children 
are considered emancipated, and do not require parent/guardian consent to participate in 
research, therefore all participating mothers provided consent autonomously. Consents for the 
participating children was given by their mothers, fathers or guardians. 
  
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy262/4995546
by London School of Hygiene & Tropical Medicine user
on 17 May 2018
Ac
ce
pte
d M
an
us
cri
pt
 
8 
 
Results 
 
Amongst participants in the Entebbe Mother and Baby Study[11], we accrued for the present 
investigation 560 HIV-negative mothers and their 567 (including twins) six-year old children 
with KSHV serological data. Socio-demographic and other characteristics of the mothers at 
enrolment are shown in Table 1. Compared to the entire EMaBS cohort, mothers 
participating in this study were more likely to have higher education and income, and less 
likely to have anaemia. 
Mothers were generally young (median 23 years, range 14-40), half had no education above 
primary school, and about a quarter had enrolled at their first pregnancy.  Mothers were 
roughly distributed between lower (42.6%) and higher (57.4%) household socioeconomic 
status (SES).  
 
Of 560 mothers and 567 of their six-year old children, whose serological data were available, 
299 (53%) and 102 (22%), respectively were KSHV seropositive. KSHV DNA was detected 
in saliva twice as frequently in seropositive children (40%, 40/99 tested) as in seropositive 
mothers (21.5%, 64/297 tested); however, while 27/56 (48%) of boys had detectable KSHV 
VL, only 13/43 (30%) of girls did (Figure 1). Amongst KSHV shedders, median KSHV viral 
load was 3.6 logs copies (IQR 2.3-4.6) in mothers, versus 4.4 (IQR 3.5-4.7) in children 
(p=0.03); there was no significant difference by sex of the child (median 4.5 logs, IQR 3.5-
4.9 in boys versus 4.4 logs, IQR 3.1-4.6 in girls).  
 
EBV DNA was prevalent in saliva of both mothers (72%, 402/559 tested) and their children 
(85% 474/560 tested); prevalence was similar in boys (84%, 232/277) and girls (86%, 
238/277) (Figure 1). However, the median viral load amongst EBV shedders was 
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significantly higher in children than in their mothers (median 4.7 logs, IQR 3.6-5.4, versus 
3.9 logs, IQR 2.4-4.7; P<0.001) and did not differ significantly by sex of the child (4.6 logs, 
IQR 3.6-5.4 in boys versus 4.8 logs, IQR 3.6-5.4 in girls).  
 
In multivariate analysis, among mothers (Table 2), a detectable KSHV VL was not associated 
with any demographic or clinical variable. KSHV shedding was directly associated with 
increasing levels of antibodies against KSHV K8.1 (medium and high optical density [OD], 
vs. low OD, Odds Ratio [OR] 80, 95% confidence interval, [CI] 11-560) and inversely 
associated with antibodies against P. falciparum AMA-1 (medium and high titres vs. low 
titres, OR 0.25, CI 0.07-0.86), but there was no association with level of antibodies against 
KSHV ORF73, nor with anti-P.f.MSP-1 antibodies. Detection of EBV DNA in mothers was 
not associated with any sociodemographic, clinical or serological factor.  
Amongst seropositive mothers shedding KSHV (Table 3), no factor was associated with 
KSHV viral load. Similarly, no factors were associated with EBV VL in EBV shedders.   
 
The children of mothers shedding KSHV were not more likely to be KSHV seropositive 
(crude OR, 1.63, CI 0.9-2.93; OR adjusted for maternal age, education, SES and sex of the 
child, 1.63, CI 0.9-2.99). In multivariate analysis, among children (Table 4), the odds of 
shedding KSHV were higher in boys versus girls (OR 2.22, CI 0.97-5.10), and in children 
with helminthiasis compared to those without (OR 7.63, CI 0.63-83.45), although the 
differences did not reach statistical significance, and the latter finding was based on only four 
children. The odds of shedding KSHV were inversely associated with antibodies against P. 
falciparum AMA-1 (medium and high titres vs. low titres, OR 0.11, CI 0.01-0.77), and 
tended to increase with higher anti-KSHV antibody levels, although there was no statistically 
significant association.  
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The odds of shedding EBV tended to be lower in children born to mothers 20 years and older 
(OR 0.3, CI 0.09-1.05) but were not otherwise associated with any sociodemographic, 
clinical or serological factor.  
Among children shedding KSHV (Table 5), VL was higher in those who had helminths, 
(+2.1 log copies, CI +0.37 to +3.83) but was not associated with any other factor, whether 
demographic, clinical or serological. 
EBV viral load was significantly higher in children in those borne of mothers with higher 
EBV VL (+0.15 log copies, CI 0.04-0.26) Furthermore, EBV viral load was lower in children 
with medium or high P.f.MSP-1 antibody levels (-1.05 log copies, CI -1.77 to -0.33). 
 
Among KSHV-seropositive participants tested for both viruses, 57% shed only EBV, 13% 
only KSHV, 13% shed both viruses and 17% did not shed either virus. Among mothers, 40% 
of KSHV shedders also shed EBV, compared to 75% of those who did not shed KSHV; for 
children, it was 65% versus 83% (Table 1S).  When examining the relationship between 
KSHV VL and EBV VL, restricting to KSHV-seropositive individuals, we found a negative 
correlation (-0.22, p<0.0001). The correlation strengthened amongst KSHV shedders (-
0.30, p<0.001). However, when restricting to EBV shedders, a modest positive correlation 
was observed (+0.15, p=0.01). Stratifying mothers and children yielded similar results 
(except that the variance was larger in the latter case, because of the smaller number of 
KSHV- seropositive children).  
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Discussion 
 
To our knowledge, this is the first study of factors associated with shedding of KSHV and 
EBV in saliva – a mechanism for viral transmission – in a sample of apparently healthy, HIV 
uninfected people, from a population in which both viruses are very prevalent and in which 
the tumours they cause, Kaposi’s sarcoma and Burkitt’s lymphoma, are endemic[20]. 
 
The prevalence of KSHV shedding was similar between mothers and their female children, 
but it tended to be higher in male children. When examining KSHV viral load in individuals 
who did shed, it was higher in children than in mothers, but similar in boys and girls.  The 
reasons for greater prevalence, and presumably frequency, of shedding among male children, 
when compared to their mothers and to female children are not clear. In two other studies of 
adults and children from Uganda examining prevalence of KSHV viral load in blood, 
Mbulaiteye and colleagues showed that males were twice as likely to have detectable virus in 
blood when compared to females [18, 21, 22]. One of these studies [21] found no difference 
in the prevalence of detectable virus in saliva between boys and girls. However, in 
combination with the fact that, among people without HIV infection, Kaposi’s sarcoma 
shows a marked excess incidence among men compared to women [23, 24], this might 
suggest that males are less able to control KSHV replication than females. Our results further 
suggest that such differential control may be established at an early age, suggesting that non-
reproductive factors might be at play, whether genetic, or environmental due to early sex- or 
gender-specific exposures/ behaviours.   
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That many more children than mothers shed also suggests that children may be an important 
source of KSHV transmission both within the family and in the wider community. Further 
studies of KSHV transmission between children are warranted.  
 
In mothers, we detected strong associations between KSHV shedding and anti-KSHV K8.1 
antibody levels; this is consistent with the hypothesis that antibodies against the K8.1 antigen 
reflect lytic viral replication [25]. Such association in children was not significant. While 
children shed more frequently, it is conceivable that the shorter time since KSHV acquisition 
did not yet result in increase of KSHV- specific antibodies compared to non-shedders; 
alternatively, or additionally, in the course of recent infection in children, the antibody 
response profile might be different than during established infection in adults.    
 
Viral load in peripheral blood mononuclear cells is more likely to be relevant to KSHV 
pathogenesis than viral load in saliva, and the correlation between it and anti-KSHV antibody 
levels will need to be investigated directly, yet, we can now confirm a previously observed 
association between anti-K8.1 antibody levels and KSHV reactivation, resulting in salivary 
shedding [8]. This further validates our previous observations on the possible role of anti-
K8.1 antibody levels as a prognostic marker in the natural history of infection [25]. 
 
In previous work within this cohort, we have identified associations between KSHV 
prevalence and malaria parasitaemia in both mothers and children [9, 10]. More recently we 
found that KSHV prevalence was also associated with antibodies against P. falciparum 
malaria (both P.f.AMA-1 and P.f.MSP-1) in both mothers and children [26]. In this study, we 
find an association between P.f.AMA-1 levels and KSHV shedding in mothers, and P.f.MSP-
1 levels and KSHV shedding in children, but not between these anti-malaria antibodies and 
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VL in shedders, either mothers or children. Further prospective research on the role of 
malaria in the natural history of KSHV infection is justified. In keeping with our previous 
findings, we also observed a sizable association between faecal detection of helminths in 
children with both KSHV shedding and viral load, although, for the former finding, the small 
number of affected children did not allow the association to reach significance. This also 
deserves further study in larger cohorts, especially in light of the recent observations that 
murine gammaherpesvirus 68 undergoes reactivation in latently infected mice acutely 
infected with intestinal helminths [27].  
 
Consistent with earlier reports, a large majority of participants (adults and children of both 
sexes) were shedding EBV[28]. Such a high proportion of shedders explains to some extent 
why, contrary to KSHV, EBV is ubiquitous in this population from a very early age. A child 
had presumably a higher likelihood of exposure to EBV than to KSHV at any given time, 
even though we detected similar VL in shedders: in children, median KSHV VL was 4.4 log 
copies (IQR 3.5-4.7), while EBV VL was 4.7 logs (IQR 3.6-5.4); in mothers, KSHV VL was 
3.6 logs (IQR 2.3-4.6), and EBV VL 3.9 logs, (IQR 2.4-4.7). Susceptibility to acquisition of 
either viral infection might also differ in the same individuals, in part because of the different 
role of exposure cofactors. 
In mothers, no factor was associated with EBV shedding nor with viral load. In children, 
however, some maternal factors were significant. Children of older mothers, tended to shed 
less, emphasizing the possible role of environmental exposures unmeasured in our study. 
Likewise, children of mothers with high EBV VL tended to shed more themselves, again 
suggesting a common exposure or perhaps a genetic factor, also worthy of further 
examination. We have recently performed a genome wide association study (GWAS) in a 
population-based rural Ugandan cohort, and we have identified association between 5 novel 
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loci and anti-EBV antibody levels [29].  Finally, we have identified negative associations 
between P.f.MSP-1 (but not anti- P.f.AMA-1) antibody levels and EBV viral load in 
shedding children (but not mothers). The relationship between EBV and malaria infections 
has been investigated since the discovery of the virus[30], and very recent data provide 
interesting insight on the role of malaria in EBV-associated lymphomagenesis[31]; yet, like 
for KSHV, the contribution of malaria to EBV pathogenesis and natural history, must be 
further investigated throughout the lifespan. 
 
For the first time, we also present data on the relationship between KSHV and EBV shedding   
in saliva. It is notable that individuals shedding KSHV tend to shed less EBV, while 
individuals shedding EBV tend to shed more KSHV. This suggests that there may be direct or 
indirect interaction between EBV and KSHV oropharyngeal replication, but the mechanisms 
controlling replication and shedding in saliva have not yet been investigated.  Sparse in vitro 
data is available on dually-infected primary effusion lymphoma lines, showing KSHV 
inhibition by EBV [32], mutual inhibition by the two viruses [33] or differential 
transactivation of the two viruses by host immune factors [34], and even synergistic in vivo 
tumorigenicity in animal models [35]. Further investigation on the interactions between the 
two human gammaherpesviruses and their host is warranted.  
 
In conclusion, this study investigates salivary shedding of KSHV and EBV infection in 
apparently healthy mothers and their children and, identifies for the first time several factors 
that influence shedding or salivary viral load, in the course of either or both infections. Our 
findings contribute to knowledge of transmission, epidemiology and natural history of EBV 
and KSHV infection in an East African population, in which the two viruses and the 
associated malignancies are endemic.  
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Authors’ summary 
Among ~500 Ugandan mother-child pairs, EBV was more likely shed in saliva than KSHV; 
several factors, including child’s sex and parasitic infections, influenced viral shedding. EBV 
and KSHV shedding were inversely related, suggesting an interaction between the two 
viruses.  
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Figure Captions 
Figure 1. Salivary shedding in mothers and children. Unadjusted proportion of mothers 
and children of either sex who are shedding KSHV are estimated on KSHV seropositive 
individuals only, whilst prevalence of EBV shedding is estimated on the entire sample, as all 
assumed to be EBV seropositive 
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Table 1: Characteristics of participating mothers (N= 560) 
Characteristics Number
a
 % 
Age group     
14-19 112 20.0% 
20-24 222 39.7% 
25-29 136 24.3% 
30-34 62 11.1% 
35+ 27 4.8% 
Education    
None/primary 264 47.2% 
Secondary 232 41.5% 
Tertiary 63 11.3% 
Marital status    
Single/divorced/separated/widower 70 12.5% 
Married 488 87.5% 
Mother’s monthly income (UGS)b    
<30,000  428 80.6% 
>= 30,000  103 19.4% 
Household socioeconomic status    
Lower 234 42.6% 
Higher 314 57.4% 
Number of pregnancies    
1 139 24.9% 
2-4 324 58.0% 
5+ 97 17.2% 
a 
Numbers do not add to total because of missing data, percentages refer to total. 
b 
30,000 Ugandan 
Shillings (UGS) corresponds to the median national income. 
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Table 2. Factors associated with shedding of KSHV and EBV in saliva among mothers 
 
Factor KSHV Shedding     EBV Shedding    
 N
a
 % aOR
b
 95% CI
b
 p
d
  N % aOR 95% CI p 
Age 
      
       
14-19 14/73 19.2% Ref. n.s.
e
 80/112 71.4% Ref.   n.s. 
20-24 24/116 20.3% 1.09 0.52 2.29   162/221 73.3% 1.10 0.66 1.85  
25-29 16/65 24.6% 1.42 0.62 3.26   93/136 68.4% 0.89 0.50 1.57  
30-34 8/29 26.7% 1.47 0.53 4.06   45/62 72.6% 1.05 0.52 2.14  
35+ 2/14 14.3% 0.72 0.14 3.65   21/27 77.8% 1.67 0.57 4.87  
Education              
Primary/none 36/147 24.2% Ref.   n.s.  191/264 72.0% Ref. 0.83  n.s. 
secondary 22/123 17.7% 0.69 0.38 1.27   167/231 72.3% 1.00 0.66 1.49  
tertiary 6/27 22.2% 0.91 0.33 2.51   44/63 69.8% 0.89 0.47 1.69  
Household SES              
lower 29/154 18.8% Ref.     168/234 71.8% Ref.    
higher 35/140 24.5% 0.70 0.40 1.24 n.s.  228/314 72.6% 1.05 0.71 1.55 n.s. 
Anaemia              
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No 35/188 18.6% Ref.     269/377 71.4% Ref.    
Yes 29/109  25.9% 1.60 0.90 2.83 n.s.  132/181 72.9% 1.13 0.75 1.70 n.s. 
Anti-KSHV antibodies OD 
ORF73              
Low 22/99 22.0% Ref.   n.s.  34/99 34.3%    n.s. 
Medium 16/99  15.0% 0.65 0.31 1.34   27/99 27.3% 1.00 0.53 1.90  
High 26/99 27.0% 1.20 0.61 2.34   33/99 33.3% 0.71 0.38 1.31  
K8.1              
Low 5/98 5.0% Ref.   <0.001  29/99 29.6%    n.s. 
Medium 25/98  25.0% 7.22 2.58 20.24   30/100 30.0% 1.36 0.73 2.53  
High 34/98 34.0% 10.61 3.87 29.12   35/99 35.4% 1.16 0.63 2.14  
Malaria antibody titres 
P.f.AMA-1              
Low 23/81 28.4% Ref.   0.02  136/183 74.3% Ref.    
Medium 21/104 20.2% 0.58 0.29 1.17   132/184 71.7% 0.87 0.54 1.39 n.s. 
High 17/110 15.5% 0.39 0.19 0.82   129/186 69.7% 0.83 0.52 1.33  
P.f.MSP-1              
Low 20/79 25.3% Ref.   n.s.  136/181 75.1% Ref.   n.s. 
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Medium 20/105 19.0% 0.60 0.29 1.25   140/185 75.7% 1.04 0.64 1.70  
High 21/111 18.9% 0.58 0.28 1.19   121/186 65.1% 0.60 0.38 0.96  
a
KSHV seropositive individuals only. 
b
Adjusted odds ratio (aOR) are estimated from multivariate logistic regression models that include age, 
education, household socioeconomic status; the first three covariates are adjusted for the other two. 
c 
CI, Confidence Interval.
 d
p values for ORs are 
from likelihood ratio tests. 
e
p<0.05 
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Table 3. Factors associated with KSHV and EBV viral load (VL) in saliva of shedding mothers  
 KSHV VL  EBV VL 
 
a
Coeff. 95% CI
b
 p
c
  Coeff. 95% CI p 
N 64  404 
Age          
14-19 Ref.   n.s.
e
  Ref.   n.s. 
20-24 -0.36 -1.61 0.90   -0.17 -0.69 0.34  
25-29 0.14 -1.24 1.52   -0.39 -0.98 0.19  
30-34 -0.71 -2.36 0.94   -0.20 -0.90 0.50  
35+ 0.71 -2.17 3.59   -0.13 -1.05 0.79  
Education          
Primary/none Ref.   n.s.  Ref.   n.s. 
secondary 0.78 -0.23 1.79   0.24 -0.17 0.64  
tertiary 1.35 -0.31 3.01   0.14 -0.51 0.79  
Household 
SES -0.03 -0.98 0.93 n.s. 
 
-0.22 -0.60 0.17 n.s. 
Anaemia -0.23 -1.22 0.76 n.s.  -0.01 -0.41 0.40 n.s. 
anti-KSHV antibodies OD 
K8.1           
Low  Ref.   n.s.  -    
Medium 0.83 -1.05 2.71   -    
High 0.94 -0.89 2.77   -    
ORF73          
Low  Ref.   n.s.  -    
Medium -0.81 -2.08 0.47   -    
High 0.46 -0.70 1.62   -    
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Anti-malaria antibodies OD 
P.f.AMA-1          
Low Ref.   n.s.  Ref.   n.s. 
Medium 0.19 -0.98 1.36   0.26 -0.20 0.72  
High 0.19 -1.08 1.46   0.28 -0.18 0.73  
P.f.MSP-1          
Low Ref.   n.s.  Ref.   n.s. 
Medium -0.09 -1.35 1.16   0.14 -0.31 0.59  
High 0.06 -1.17 1.29   0.36 -0.10 0.83  
a
Coefficients expressing variation in log10 GE/million cells are estimated in shedding individuals only, 
from multivariate models that include age, education and household SES; first three covariates adjusted 
for the other two. 
b
CI, Confidence Interval.
 c
p values for coefficients are from likelihood ratio tests.
 
e
p<0.05 
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Table 4. Factors associated with shedding of KSHV and EBV in saliva among children 
Factor KSHV Shedding     EBV Shedding    
 N
a
 (%) aOR
b
 95% CI
b
 p
b
  N (%) aOR 95% CI p 
Sex              
F 13/43 30.2% Ref.     238/277 85.9% Ref.    
M 27/56 48.2% 2.15 0.93 4.96 n.s.
e
  232/277 83.8% 0.72 0.30 1.73 n.s. 
Maternal Age 
      
       
14-19 6/14 42.9% Ref. n.s.  100/110 90.9% Ref.   0.05 
20-24 15/36 41.7% 0.89 0.25 3.18   186/224 83.0% 0.28 0.07 1.09  
25-29 10/29 34.5% 0.72 0.19 2.73   111/131 84.7% 0.36 0.08 1.52  
30-34 6/11 54.5% 1.36 0.27 6.92   54/63 85.7% 0.42 0.07 2.34  
35+ 3/9 33.3% 0.54 0.09 3.19   20/27 74.1% 0.10 0.01 0.98  
Parity              
1 12/22 54.5% Ref.   n.s.  114/135 84.4% Ref.   n.s. 
2-4 16/55 29.6% 0.37 0.13 1.06   279/324 86.1% 1.27 0.45 3.62  
5+ 12/23 52.2% 0.90 0.27 2.94   78/96 81.3% 0.66 0.17 2.52  
Maternal shedding              
No 29/68 42.6% Ref.     124/150 82.7%     
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Yes 4/17 23.5% 0.39 0.11 1.33 n.s.  338/396 85.4% 1.23 0.74 2.04 n.s. 
Anaemia              
No 29/77 37.6% Ref.     367/430 85.3% Ref.    
Yes 11/22  50.0% 1.51 0.57 3.98 n.s.  107/130 82.3% 0.63 0.23 1.76 n.s. 
Helminths              
No 15/41 36.5% Ref.     251/287 87.6% Ref.    
Yes 3/4 75.0% 7.23 0.63 83.45 n.s.  14/18 77.8% 0.18 0.01 5.52 n.s. 
anti-KSHV antibodies OD 
ORF73               
Low 11/33 33.3% Ref.   n.s.  9/33 27.3% Ref.   n.s. 
Medium 12/33 36.4% 1.28 0.45 3.63   9/33 27.3% 0.86 0.28 2.65  
High 17/33 51.5% 2.60 0.92 7.38   6/33 18.2% 1.39 0.41 4.66  
anti-K8.1              
Low 12/33 36.4% Ref.   n.s.  4/33 12.1% Ref.   n.s. 
Medium 9/33  27.3% 0.55 0.19 1.61   11/33 33.3% 0.33 0.09 1.23  
High 19/33 57.6% 2.06 0.75 5.70   9/33 27.3% 0.45 0.12 1.71  
anti-Malaria antibody titres 
P.f.AMA-1              
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Low 11/24 45.8% Ref.   n.s.  157/184 85.3% Ref.    
Medium 11/25 44.0% 1.02 0.32 3.23   152/186 81.7% 0.58 0.20 1.69 n.s. 
High 17/48 35.4% 0.67 0.24 1.86   157/182 86.3% 1.06 0.37 3.05  
P.f.MSP-1              
Low 14/23 60.9% Ref.   0.03  157/186 84.4% Ref.   n.s. 
Medium 12/36 33.3% 0.32 0.11 0.97   161/185 87.0% 1.46 0.50 4.27  
High 13/38 34.2% 0.33 0.11 1.00   148/181 81.8% 0.65 0.23 1.85  
a
KSHV seropositive individuals only. 
b
Sex -adjusted odds ratio (aOR), except when sex is the factor. 
c 
CI, Confidence Interval.
 d
p values for ORs 
are from likelihood ratio tests.
 e
p<0.05 
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Table 5. Factors associated with KSHV and EBV viral load in saliva of shedding children.  
 KSHV VL  EBV VL 
 
Coeff.
 a
 95% CI
b
 p
c
  Coeff. 95% CI p 
N 40  477 
Male Sex -0.10 -1.19 0.99 n.s.
e
  0.20 -0.14 0.56 n.s. 
Maternal Age          
14-19 Ref.   n.s.  Ref.   n.s. 
20-24 1.03 -0.53 2.60   -0.05 -0.52 0.42  
25-29 1.22 -0.46 2.89   -0.17 -0.69 0.35  
30-34 0.34 -1.52 2.21   -0.34 -0.98 0.30  
35+ 2.05 -0.29 4.39   -0.23 -1.16 0.70  
Parity Ref.   0.05  Ref.   n.s. 
2-4 1.29 0.09 2.50   -0.25 -0.67 0.17  
5 or more 0.91 -0.36 2.19   -0.20 -0.76 0.36  
Maternal VL
 d
 -3.83 -16.54 8.89 n.s.  0.15 0.04 0.25 0.007 
          
Anaemia 0.09 -1.07 1.25 n.s.  -0.21 -0.62 0.21 n.s. 
          
Helminths 2.10 0.37 3.83 0.02  -0.16 -1.26 0.93 n.s. 
K8.1 OD           
Low Ref.   n.s.  -    
Medium -0.14 -1.60 1.32   -    
High 0.63 -0.67 1.93   -    
ORF73 OD          
Low Ref.   n.s.  -    
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Medium 0.54 -0.83 1.90   -    
High 0.09 -1.22 1.39   -    
pfAMA-1 OD          
Low Ref.   n.s.  Ref.   n.s. 
Medium 0.63 -0.79 2.05   -0.19 -0.62 0.25  
High 0.11 -1.22 1.45   -0.08 -0.51 0.35  
pfMSP-1 OD          
Low Ref.   n.s.  Ref.   0.01 
Medium -0.35 -1.78 1.07   -0.37 -0.75 0.02  
High -0.12 -1.47 1.24   -0.55 -0.97 -0.12  
a
Coefficients expressing variation in log10 GE/million cells are estimated in shedding individuals only 
and sex adjusted, except when sex is the factor. 
b
CI, Confidence Interval.
 c
p values for coefficients are 
from likelihood ratio tests.
 d
 Corresponding maternal VL scaled in log10 copies increments. 
e
p<0.05 
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Figure 1. 
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